Technology
Isomorphic Labs and MSD set to collaborate on AI-led cancer drug discovery
Alphabet-owned Isomorphic Labs and MSD are set to collaborate on a research project combining Isomorphic's AI technology with MSD's data resources and experience. The partnership aims to discover therapeutic small molecule candidates against an oncology target of strategic importance, which means searching for potential new cancer drugs aimed at a prioritised target.
Isomorphic Labs will use in silico prediction, meaning computer-simulated experiments, to deliver drug molecule designs, and will apply MSD's datasets to its own drug design engine, IsoDDE. MSD's involvement will cover pre-clinical and clinical development, manufacturing and bringing any resulting medicines to market.
Under the agreement, Isomorphic Labs will receive an upfront payment from MSD and will also be eligible for milestone payments linked to specified research, development, regulatory and commercial achievements. Earlier this week, Isomorphic Labs announced it had raised $5bn in Series C funding, co-led by Greenoaks and Sequoia Capital.
Sarah Skerratt, chief research officer at Isomorphic Labs, said the deal would let the company apply its world-leading drug design engine to unlock significant discovery progress. George Addona, senior vice-president at MSD Research Laboratories, said close coordination of wet-lab and dry-lab work was key and that the aim was to design better candidates faster.
Key points
- Alphabet-owned Isomorphic Labs and MSD are set to collaborate on AI-led discovery of potential new cancer drugs.
- Isomorphic Labs will apply MSD's datasets to its own drug design engine, IsoDDE.
- MSD will handle pre-clinical and clinical development, manufacturing and bringing any resulting medicines to market.
- Isomorphic Labs will receive an upfront payment and will be eligible for milestone payments.
- Earlier this week Isomorphic Labs announced it had raised $5bn in Series C funding.
Coverage from
This story was put together automatically from the sources above. Open a source to read its original report. How nuze makes stories